J
Jun Yi Zhang
Publications - 7
Citations - 57
Jun Yi Zhang is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 1 publications receiving 10 citations.
Papers
More filters
Journal ArticleDOI
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
Shengjie Tang,Chao Qin,Haiyang Hu,Tao Liu,Yiwei He,Haiyan Guo,H. Yan,Jun Yi Zhang,Shou-Bai Tang,Haining Zhou +9 more
TL;DR: In this paper , the authors describe clinical trials using ICI immunotherapies for NSCLC treatment, the available data on clinical efficacy, and the emerging evidence regarding biomarkers.
Journal ArticleDOI
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
Claire N. Harrison,Nicolaas Schaap,Alessandro M. Vannucchi,Jean-Jacques Kiladjian,Francesco Passamonti,Sonja Zweegman,Moshe Talpaz,Srdan Verstovsek,Shelonitda Rose,Jun Yi Zhang,Oumar Sy,Ruben A. Mesa +11 more
TL;DR: Evaluated data indicate that fedratinib 400 mg/day is safe and effective in patients with myelofibrosis and low pretreatment platelet counts, and no initial fedrat inib dose adjustment is required for these patients.
Journal ArticleDOI
Clinical practice guidelines on cancer-related anemia (2012-2013 Edition)
Yan Sun,Mei Lin Liao,Zhongzhen Guan,Ji Feng Feng,Bing Hu,Cheng Huang,Jin Li,Xian Ling Li,Jiwei Liu,Wen Chao Liu,Xiao Qing Liu,Yun Peng Liu,Shun Lu,You Lu,Jun Ma,Xue Zhen Ma,Shu kui Qin,Yuan Kai Shi,Jianmin Wang,Jie Jun Wang,Yajie Wang,Zhehai Wang,Wang Lin,Yang Yao,Shi Ying Yu,Ming Zhi Zhang,Li Zhang,Jun Yi Zhang,Yiping Zhang,Yue Zhang,Jun Zhu,Yao Wang +31 more
Journal ArticleDOI
Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer
Ethan Burns,Kelly Gee,Ryan B. Kieser,Jiaqiong Xu,Yuqi Zhang,Aubrey Crenshaw,Ibrahim N. Muhsen,Charisma Mylavarapu,Abdullah Esmail,Shivan Shah,Godsfavour Umoru,Kai Sun,Carlo Guerrero,Zimu Gong,K. Heyne,Monisha Singh,Jun Yi Zhang,Eric H. Bernicker,Maen Abdelrahim +18 more
TL;DR: In this article , the authors assessed the incidence, type, and impact of infection on morbidity and mortality in non-small cell lung cancer patients receiving pembrolizumab-based therapies.
ReportDOI
The efficacy and safety of immune-checkpoint inhibitor plus chemotherapy versus chemotherapy for non-small cell lung cancer: an updated systematic review and meta-analysis
TL;DR: A large number of histologically confirmed advanced NSCLC patients received immune-checkpoint inhibitor plus chemotherapy, while the control group received chemotherapy, and the results indicated that the former was more beneficial than the latter.